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Background: Chronic airway infection with methicillin-resistant Staphylococcus aureus (MRSA) in patients with cystic ﬁbrosis (CF) is an
increasing clinical problem, and therapeutic options are limited. Because chronic infection with MRSA can be associated with accelerated decline
in lung function, eradication of MRSA is attempted in most CF centres today. The aim of this observational prospective cohort study was to
determine whether it is possible to eradicate MRSA from airways of CF patients using prolonged oral antibiotic combination therapy together with
topical decolonization measures.
Results: Eleven CF patients, (median age: 9 years (range 1–43); median FEV1: 91%pred (95%CI 74%–100%pred)) who were chronically infected
with MRSA, were treated daily for six months with rifampicin and fusidic acid orally. This study did not include a patient control group. Two
patients had to switch to an alternative schedule, using rifampicin and clindamycin, due to the resistance pattern of MRSA. Topical decolonization
measures were applied to all patients and included mupirocin-containing nasal ointment in both nostrils three times daily for ﬁve days and
chlorhexidine hair and body wash once daily for ﬁve days. Microbiological eradication was achieved in all patients at the end of the six-month
eradication protocol, even when signiﬁcant time (range 18 months to 9 years) had elapsed since initial isolation. In only one patient MRSA
reappeared in the six-month follow-up period after the initial study period. Side-effects, like nausea, vomiting and diarrhoea were seen in ﬁve out
of eleven patients, but did not lead to therapy cessation.
Conclusion: Chronic MRSA infection can be eradicated from respiratory tract samples using a six month dual antibiotic regimen and topical
MRSA decolonization measures.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
With improved survival due to improvements in care in cystic
fibrosis (CF), we are now faced with new and more resistant
pathogens such as methicillin-resistant Staphylococcus aureus
(MRSA). Data from the US CF Patient Registry show an increase
in prevalence of MRSA infection in the CF population in the US
from 2% in 1999 to 22.6% in 2008 [1]. Possible explanations for⁎ Corresponding author at: Respiratory Division, University Hospital UZBrussel,
Laarbeeklaan 101, 1090 Brussels, Belgium. Tel.: +32 2 477 4675; fax: +32 2 477
6352.
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1569-1993/$ -see front matter © 2013 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2013.04.009this rise could be the use of antibiotics, frequent hospital
admissions and the increasing mean age of the CF patients.
Chronic infection with MRSA in the CF population of the
University Hospital of Brussels amounted to 12.6% in 2010 [2]
and was associated with frequency of hospitalization, the use
of broad-spectrum antibiotics and the presence of bronchiectasis
[2]. Before the 1990s, MRSA isolates were clearly associated
with hospitalization (HA-MRSA), but since then community-
associated strains emerged (CA-MRSA). CA-MRSA differs in
genetic background from HA-MRSA and tends to be resistant
to fewer antibiotic classes, but can be more virulent than the
HA-MRSA strains, due to the carriage of virulence factors. Given
outbreaks of CA-MRSA in the hospital or spreading ofby Elsevier B.V. All rights reserved.
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CA-MRSA becomes increasingly difficult [3].
The impact of chronic infection with MRSA on lung function
or exacerbation frequency remains uncertain, and previous
studies have failed to reach clear consensus on this matter.
Dasenbrook et al. examined the impact of MRSA acquisition on
lung function and found that the rate of FEV1 decline was greater
in the MRSA-positive patients aged 8–21 years [4]. In another
study from the group of Dasenbrook, chronic MRSA infection
was also shown to have a negative impact on survival, even after
adjusting for severity of illness [5]. Ren and colleagues showed
that CF patients colonized with MRSA have lower lung function
values and an increased rate of hospitalization [6]. Conversely,
Sawicki et al. also showed an association between MRSA
detection and CF disease severity, but a negative effect on lung
function decline was not noted in this study [7]. In a recent study
from our group, we could demonstrate a more rapid decline in
FEV1 in CF patients colonized with MRSA compared to non-
colonized CF patients, despite comparable FEV1 values in both
groups one year prior to the initial infection with MRSA. From
our limited data we could conclude that FEV1 itself was not a
predictor for infection with MRSA, but it can provoke a more
rapid FEV1 decline [2]. The pathogenesis by which MRSA
could lead to more rapid lung destruction is not fully revealed.
Staphylococci can harbour a multitude of virulence factors,
including membrane-damaging toxins, that promote bacterial
spread in tissues. The leukocytolytic toxin Panton–Valentine
Leukocidin (PVL) is more frequently expressed in MRSA than
methicillin-sensitive S. aureus (MSSA) strains. PVL has been
associated with severe and necrotizing lung infections [8]. Except
for the impact on lung function, MRSA infection has also other
important implications for patients with CF. Segregation of
patients is recommended, to prevent patient-to-patient transmis-
sion in CF as well as in non-CF individuals [9]. Strict isolation
measures can have negative psychological impact and lead to
depression, as shown by Tarzi et al. [10]. There is no strong
consensus regarding the management of chronic MRSA infection
in CF patients. A prophylactic protocol to prevent chronic
infection in MRSA negative patients could enhance emergence
of further resistance. Since decades there is reasonable evidence
that MSSA can be eradicated from sputum with antibiotics [11],
but to date there is no conclusive evidence that early aggressive
treatment of MRSA respiratory infection can prevent chronic
colonization or improves outcome. Several potential antibiotic
regimes have been reported to achieve eradication [12–18]. In
most of the studies successful eradication was achieved, using
systemic antibiotics whether or not combinedwith topical therapy.
In 2008, the UK CF Trust has also published a report which
advocates eradication treatment for chronic MRSA infection [19].
The cystic fibrosis centre of the University Hospital of
Brussels, a large university unit, has a strict isolation policy for
MRSA-positive patients. In-patients are isolated in well-ventilated
single rooms and are barrier-nursed throughout their stay. All
patients in our facilities have their individual nebuliser compressor
systems, oxygen delivery devices and airway clearance devices,
using a strict disinfection protocol for all of them. Since the
beginning of 2011 we pursued an eradication protocol forchronically MRSA-infected CF patients, consisting of a combi-
nation of topical decolonization measures and two oral antibiotics
administrated daily for a period of six months. We conducted this
prospective study to examine the efficacy, tolerance and feasibility
of this eradication protocol.
2. Methods
This prospective observational cohort study was conducted
at the University Hospital of Brussels, Belgium from January 2011
to March 2013. The study was approved by the local ethics com-
mittee (BUN143201213745-registration no ISRCTN69078742)
and patients provided written informed consent. Sputum as well
as throat-swabs (in non-sputum-producers) were obtained by
the CF physiotherapist. Samples, collected at outpatient clinic
visits or during hospitalization, were cultured for MRSA in the
reference laboratory of the University Hospital of Brussels. Ad-
ditionally MRSA carriage was determined by collecting nose–
throat–perineum swabs. Respiratory samples were processed by
routine methodologies for CF specimens as described before [20].
S. aureus isolates were identified by coagulase test and latex
agglutination test. Antibiotic susceptibility of isolates was tested in
vitro, using phenotypic methods (selective media containing
antibiotics, disk diffusion assay and MIC by microdilution).
Chronic MRSA infection was diagnosed if at least three res-
piratory tract samples (sputum or oropharyngeal swabs) were
positive for MRSA for a period of at least six months prior to
the study. Respiratory tract samples remained MRSA positive in
all patients from date of first isolate to inclusion date. Two
out of eleven patients were not able to produce sputum sam-
ples throughout the study period. Strict isolation measures for
MRSA-positive patients, based on infection control principles,
were applied. All current MRSA positive patients (n = 15) from
the registry of the CF centre of the University Hospital of
Brussels [2] were screened to participate to the trial. Two patients
were excluded due to chronic liver failure. Two patients refused
to take part in the trial due to additional treatment burden. This
study did not include a patient control group, and all patients were
treated identically according to the study protocol. All included
patients were in a stable condition. First line choice oral anti-
biotics consisted of oral rifampicin 15 mg/kg/day and fusidic acid
30 mg/kg daily during 6 months. Rifampicin and fusidic acid
were chosen because of the enhanced penetration of these drugs
into the airway lining fluid. In case of resistance, other regimens
of bi-therapy were chosen, such as rifampicin–clindamycin or
fusidic acid–clindamycin depending on the antibiotic suscepti-
bility results. Topical decolonization measures were applied
simultaneously to all the patients and included mupirocin-
containing nasal ointment in both nostrils three times daily for
five days and chlorhexidine hair and body wash once daily for
five days. After the initial 6-month eradication-treatment an
observational period of 6 months was applied to survey MRSA
recurrence. Successful microbiological eradication was defined
as the presence of three consecutive negative MRSA screens
(sputum and surface screening swabs) over this period, following
initial eradication treatment. Spirometric data (i.e. FEV1) were
recorded at the start and the end of the eradication protocol and at
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formed using a Friedman test.
3. Results
3.1. Patient demographics
Eleven patients out of 15 screened MRSA positive patients
were enrolled in the eradication protocol. Two patients were
rejected due to chronic liver failure, two others refused to take part
due to the additional treatment burden (Fig. 2). Median age of the
study group was 9 years (range 1–43 years). Three patients had
CF related diabetes and none was pancreas sufficient. Seven out of
eleven patients were also chronically colonizedwith Pseudomonas
aeruginosa. Six out of eleven patients were homozygous for
genotype F508del. Seven out of 11 patients were MRSA carriers
on nose–throat–perineum swabs. Median FEV1 before eradica-
tion was 91%pred (95%CI 74%–100%pred). Clinical parameters
are shown in Table 1. In vitro sensitivity testing of the isolates,
cultured immediately before eradication, revealed all eleven
isolates to be sensitive to rifampicin, and nine to fusidic acid.
3.2. Eradication protocol
Topical decolonization measures were applied to all the
patients and included mupirocin-containing nasal ointment three
times daily and chlorhexidine hair and body wash once daily both
during 5 days. First choice eradication protocol consisting of
rifampicin 15 mg/kg and fusidic acid 30 mg/kg daily for a total
period of six months was completed by 9 of the 11 patients. Two
patients had to switch to a combination of rifampicin and
clindamycin (one after two weeks, and one after four weeks),
based on the susceptibility pattern of the MRSA strain.
Currently, all patients have completed the full treatment
course. All patients achieved microbiological eradication after
the six months treatment. All eleven patients were included in a
follow-up period of at least six months. Seven out of 11 patients,
who were also MRSA carriers on nose–throat–perineum swabs,
were successfully decontaminated. Results of respiratory tract
samples at different times during eradication and follow-up areTable 1
Clinical characteristics of study population.
Genotype First MRSA
isolate
Sample
type
MRSA
carrier
Age (years) CFRD P
a
F508del/F508del 1/03/2007 Swab N 4 N Y
F508del/F508del 13/02/2010 Sputum Y 9 N Y
F508del/F508del 28/12/2004 Sputum Y 43 Y Y
S1255P/F508del 14/03/2007 Sputum Y 12 N N
F508del/F508del 15/12/2008 Sputum Y 8 N Y
F508del/F508del 22/05/2008 Sputum Y 11 Y Y
F508del/F508del 29/06/2006 Sputum Y 6 N Y
F508del/R553X 7/10/2010 Sputum N 6 N Y
S1251N/L927P 29/09/2011 Swab N 1 N N
R1162X/F508del 20/08/2011 Sputum N 27 N N
S1255P/F508del 20/11/2011 Sputum Y 25 Y N
MRSA carrier = carrier on peripheral skin swabs, CFRD = cystic fibrosis related
aeruginosa, mo = months from start eradication, N = no, Y = yes, 0 = negative, 1shown in Table 1. Until now, we cultured MRSA in one patient
(who was initially MRSA negative after the eradication
treatment) four months after the end of the eradication protocol.
This treatment failure was due to lack of adherence to the
treatment. All skin swabs remained negative after decolonization,
even in patient no. 4 who cultured MRSA again during the
follow-up period. Adverse events, in particular nausea, vomiting
and diarrhoea occurred in five out of the eleven patients during
eradication. These side effects occurred in particular in the first
and last months of the treatment, but did not lead to early
treatment cessation. Spirometric data (FEV1 in particular) during
the eradication protocol and follow-up period is shown in Fig. 1.
Median FEV1 at the start of the study was 91%pred (95%CI
74%–100%pred). Median FEV1 at the end of the follow-up
period (t = 12 months) was 96%pred (95%CI 85%–104%pred).
Patient no. 4, represented by open circles in Fig. 1, cultured
MRSA again during the follow-up period. Excluding this patient
for further statistical analysis, a trend towards improvement
in FEV1 was seen, but it did not reach statistical significance
(p = 0.09, Friedman test). Until this time, none of the patients
cultured any new P. aeruginosa or other Gram-negative bacteria
during or after the eradication protocol.
4. Discussion
The aim of this trial was to examine feasibility, tolerance and
efficacy of microbiological MRSA eradication using a combina-
tion of topical decolonization measures and a 6 months oral
antibiotic bi-therapy regimen in CF patients. With this study
protocol we could offer a generally well-tolerated treatment in CF
patients ranging 1–43 years, who harboured MRSA for years
before eradication.
In our centre prevalence of chronic infection with MRSA in
CF amounted to 12.6%, despite a strict infection control regime,
which includes segregation of the patients, barrier nursing and
the use of individualized nebuliser, oxygen delivery and airway
clearance devices.
Previously, many centres have attempted the eradication of
MRSA. The optimal regimen to eradicate chronic MRSA
remains unclear, and a recent Cochrane review concluded that—seudomonas
eruginosa
Bronchiectasis BMI Respiratory tract sample MRSA status
0 3 mo 6 mo 9 mo 12 mo
Y 14.1 1 0 0 0 0
Y 14.5 1 0 0 0 0
Y 20.9 1 0 0 0 0
Y 19.1 1 1 0 0 1
Y 15.1 1 1 0 0 0
Y 18.1 1 0 0 0 0
Y 16.6 1 1 0 0 0
Y 15.1 1 0 0 0 0
N 15.7 1 1 0 0 0
Y 16 1 1 0 0 0
Y 21 1 0 0 0 0
diabetes, Pseudomonas aeruginosa = chronic colonisation with Pseudomonas
= positive.
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Fig. 1. FEV1 at start of eradication therapy (time 0) and after 3, 6, 9 and 12 months.
The grey area illustrates the eradication treatment period. Patient number 4
(represented by open circles) cultured MRSA in follow-up period.
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made to support a particular treatment protocol. Several studies
have been conducted to examine the feasibility and efficacy of
different eradication protocols using combinations of oral,
intravenous and inhaled antibiotics. A step-wise eradication
protocol using rifampicin, fusidic acid and teicoplanin has been
developed in CF centres in Belfast [12]. Of the 17 patients in that
study, 8 (47%) were successfully decolonized following a single
five-day course of rifampicin and fusidic acid. The success rate
increased to 71% and 94% after a second five-day course of oral
treatment and a course of intravenous teicoplanin respectively.
Solis et al. reported successful eradication in 7 out of 12 patientsN=19 
MRSA positive CF patients 
2010, ref2
N=15 
MRSA positive CF patients 
screened for eradication
N=11 
MRSA positive CF patients 
enrolled in eradication protocol
2 patientsdied
2 patients
transplanted
2 patients
rejected (chronic
liver failure)
2 patients refused
Fig. 2. Screening and enrolment protocol for the study. From the 19 MRSA
positive patients in 2010, eleven were enrolled in the eradication protocol.for a mean of 12 months using topical and nebulised vancomycin
during 5 days [13]. Although until now no vancomycin-
intermediate (VISA) and vancomycin-resistant (VRSA) S. aureus
have been cultured in the CF population due to prolonged use of
inhaled vancomycin. However we should remain vigilant for this
theoretical possibility, given that this is still the main option for
treating serious MRSA infections. Recently, Doe et al. achieved
eradication of MRSA in 81% (31 out of 37) of chronically
colonized CF patients using different eradication protocols [21]
chosen according to the susceptibility pattern of the MRSA
strain. Nebulised vancomycin was used in combination with two
oral antibiotics for a minimum of six weeks. First line choices
included fusidic acid, rifampicin, and trimethoprim. In some
cases, up to three courses of antibiotic treatment were required to
achieve eradication. Topical decolonization methods were used
to treat oral, skin and nasal carriage. At the adult cystic fibrosis
centre in Brisbane seven adult CF patients were treated with a
six-month course of rifampicin and sodium fusidate [16]. The
mean follow-up of this treatment protocol was six months. In five
of the seven patients eradication of MRSA was successful and a
significant reduction in intravenous antibiotic treatment days over
a subsequent period of six months (51 versus 33 days) was seen.
In this treatment protocol no topical decolonization was used to
clear chronic skin carriage.
Since mono-therapy with only one oral antibiotic probably
lacks effectiveness and may lead to increased resistance, we
opted for a bi-therapy combining two antibiotics, with drugs for
which long-term treatment is known to be generally well
tolerated. This combination of oral antibiotics is not routinely
used for CF gram-negative bacteria, so that induction of
resistance in other CF-specific bacteria is probably not an issue.
A total duration of six months was proposed since short-term
use may lead to early relapse. None of the patients failed to
complete the full treatment course and their side-effects were
tolerated. Eradication was successful in all patients, even
though 50% of them had harboured MRSA for many years
before eradication (18 months–9 years). One patient, who was
initially MRSA-negative after eradication, cultured MRSA
during the follow-up period. This MRSA strain showed the
same susceptibility pattern as before eradication. Treatment
failure in this patient was most probably due to lack of
adherence to the eradication treatment. In this study respiratory
tract samples and surface screening swabs were taken routinely
every three months and whenever patients were seen at the
outpatient clinic or in hospital. In six out of eleven patients
respiratory tract samples were MRSA-negative after three
months of eradication treatment (Table 1). We did not see an
association between the duration of the infection or the presence
of positive skin swabs and the time to sputum negativity.
Duration of eradication treatment remains debatable. Prolonga-
tion of treatment can diminish risk of false-negative cultures,
mainly in the case of oropharyngeal swabs. Conversely, longer
duration of treatment can enhance treatment burden and side
effects, and influence adherence negatively. We suspect that the
success of rifampicin and fusidic acid as an effective therapy for
MRSA in CF patients may be due to the enhanced penetration of
these drugs into the airway lining fluid, compared to vancomycin
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of oral drug, but its use is limited by cost and the lack of clinical
data in patients with CF. Moreover, prolonged or repeated
courses have been reported to potentially cause irreversible
neuropathy [23] and resistance of MRSA strains to linezolid has
been described in CF patients with MRSA [24]. We also suspect
that combining oral medication with topical measures to clear the
carriage of MRSA contributed to the eradication success.
There are some limitations to our study design. This is a small
and non-controlled trial, and interpretation of the results— and
causality in particular — is therefore limited. No control group
was chosen, because the local ethics committee did not agree on
withholding a potential beneficial treatment. Two patients were
not able to produce sputum samples. Oropharyngeal swabs could
lack sensitivity for detecting MRSA and other bacteria, but
their specificity is acceptable, so false-positive results are rare.
Molecular strain typing of MRSA strains was not performed in
this study. Molecular typing could aid in identifying strains and
evaluating possible patient-to-patient transmission or other
sources of contamination. Household members and staff, which
could be sources of re-infection, were not routinely screened in
this study, but followed hospital guidelines on barrier nursing and
isolation. The chronic use of parenteral, oral or nebulised
antibiotic therapies was similar during each six-month period of
study. However, some of these antibiotics can have an anti-
staphylococcal effect and could be considered a confounding
factor. The balance between ensuring effective eradication of
MRSA against potential adverse events and treatment burden
must be sought. Six out of eleven patients did not culture MRSA
after three months of treatment, so duration of treatment could
perhaps be shortened. Nevertheless, cultures of respiratory tract
samples can be false-negative and relapses can occur if
eradication treatment is too short. Giving a certain treatment, we
should also always stay vigilant for the fact that eradication of one
microbiological agent can theoretically encourage the growth and
colonization of other pathogens, e.g. P. aeruginosa.
In conclusion, this study shows that it is possible to achieve
successful eradication after several years of MRSA infection. A
large randomised trial, including long-term follow-up to assess
the risk for re-infection of MRSA, is required to investigate the
role of this combination therapy on the eradication of chronic
MRSA infection, the duration of the eradication and to
establish possible beneficial effects on pulmonary status.
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